Emma Scott

Prostate Cancer UK Research Fellow @ Newcastle Uni. O-glycans, Siglecs and the prostate tumour immune microenvironment.

[Emma Scott @EScottScience]

Here’s the final version of the first paper from our lab. Standard therapies used to treat prostate cancer regulate glyco-immune checkpoints. We’re doing a lot more on this so watch this space!

https://t.co/bIGDWqZrxz

@ProstateUKProfs @nubiosciences @NU_Cancer #glycotime

[Emma Scott @EScottScience]

@ProstateUKProfs

[Emma Scott @EScottScience]

Interested in doing a PhD in tumour immunology? We’re looking for a keen and enthusiastic student to join our group!

https://t.co/6dC9gJSzZ8

📧 Please get in touch if you’d like to chat further ([email protected])

[ProstateUK Profs @ProstateUKProfs]

Coming soon! 📢

Applications for our Career Acceleration Fellowships open in March.

We’re offering up to £350K over 3-4 years to support early career prostate cancer researchers to advance their career and build collaborations.

🚨Find out more here: https://t.co/8wGTrWw4ik

[Emma Scott @EScottScience]

I have previously attended these brilliant events for ECR’s and can’t emphasise enough how valuable they have been. A great way to keep up with the latest research, get some additional training and meet new collaborators!

[ProstateUK Profs @ProstateUKProfs]

📣 We're excited Making Progress, our event for Early Career Researchers, will be back in 2025.

📆 Save the date and look out for updates including how to register for the event that will help you become the next leader in the field.

📙 Read more: https://t.co/9HjaRunvYi

[Robertslab @Robertslab1]

Very happy to share my thoughts about the importance of allyship with @CRUKresearch. Thanks to everyone involved in our EDI @CRUK_SI who helped me shape my thoughts!

https://t.co/3JsEZ52StZ

[Emma Scott @EScottScience]

A comprehensive discussion about methods of detection of anti-Neu5Gc antibodies by brilliant @DiMeN_DTP student @eshutton1. It’s a joy to be involved with this project led by such a talented student @UniOfYork @nubiosciences. Congrats Esme!

[Es @eshutton1]

Started life as a spreadsheet of experiment conditions to try, ended up as the first paper of my PhD- see below for the review I wrote about strategies to detect anti-Neu5Gc antibodies in humans!

https://t.co/NZLrRoEnmq

[Newcastle FCCF @NewcastleFCCF]

@bioImaging_NCL @YorkBioimaging @NCL_IMA @nu_scan

[Susan Heavey @susan_heavey]

Enjoyable session on overcoming treatment resistance - reckon we should find something else to co-host, @ethansgrumps what do you reckon? 😁

Thanks to our esteemed speakers @EScottScience Johann DeBono @royalmarsdenNHS @BevanLab @eileen_parkes @JCarrollLab 🔬#FITI24 @ProstateUK

[Emma Scott @EScottScience]

Thrilled that the first session of the Prostate Cancer UK From Ideas to Innovation meeting is underway! @ProstateUKProfs #FITI24

[ARCS Foundation – San Diego @SanDiegoARCS]

Meet @BrettGarabedian #ARCSScholar @scrippsresearch who uses chemistry & protein engineering to empower our immune system against diseases, including chronic infection & cancer. Join us April 27 (4-8 pm) at our SOY event to honor our Scholars! More info:
https://t.co/yIfJ6RJHul

[Emma Scott @EScottScience]

@BrettGarabedian 100% would hypothesise that they would!

[ProstateUK Profs @ProstateUKProfs]

📢 What role do therapies targeting glyco-immune checkpoints have in #prostatecancer?

Dr Emma Scott and colleagues at @NU_Cancer and beyond show ST3Gal1 is critical to anti-tumour immunity. Congratulations publishing in @CommsBio

Grab a ☕and read now: https://t.co/g4Fa79LH2k

[Emma Scott @EScottScience]

@NiTriona @rebeccagarnham1 Thank you!

[Emma Scott @EScottScience]

@MichaelodwyerMD @RebeccaGarnham @Palleon_Pharma @Glycotime @CarolynBertozzi @aideenryan1 Thank you Michael! Super important that we pursue this to improve treatment options for patients

[Emma Scott @EScottScience]

@NatashaHepburn4 Thanks Natasha!

[Emma Scott @EScottScience]

@ahmadurology @ProstateUKProfs @nubiosciences @NU_Cancer Thanks Imran - hope things are going well!

[Emma Scott @EScottScience]

Here’s the final version of the first paper from our lab. Standard therapies used to treat prostate cancer regulate glyco-immune checkpoints. We’re doing a lot more on this so watch this space!

https://t.co/bIGDWqZrxz

@ProstateUKProfs @nubiosciences @NU_Cancer #glycotime

[Emma Scott @EScottScience]

@salva_iborra @rebeccagarnham1 Thank you!

[Emma Scott @EScottScience]

@KirstCampbe11 @ProstateUKProfs @nubiosciences @NU_Cancer @rebeccagarnham1 Thanks Kirsteen - hope you’re getting on okay!

[Emma Scott @EScottScience]

@AsmaAhmedHassan @ProstateUKProfs @nubiosciences @NU_Cancer Thanks Asma! Looking forward to hopefully catching up at the PCUK meeting soon!